Cargando…

Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients

BACKGROUND: Epstein-Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is a common subtype of HLH with heterogeneous clinical presentations from self-limited to death, of which adults are worse than children. OBJECTIVE: To establish predictors of mortality risk in adult EBV-HLH...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Shuyan, He, Lingbo, Zhang, Ruoxi, Liu, Menghan, Hua, Zhengjie, Zou, Heshan, Wang, Zhao, Wang, Yini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9766494/
https://www.ncbi.nlm.nih.gov/pubmed/36533966
http://dx.doi.org/10.1080/07853890.2022.2149850
_version_ 1784853743746940928
author Yao, Shuyan
He, Lingbo
Zhang, Ruoxi
Liu, Menghan
Hua, Zhengjie
Zou, Heshan
Wang, Zhao
Wang, Yini
author_facet Yao, Shuyan
He, Lingbo
Zhang, Ruoxi
Liu, Menghan
Hua, Zhengjie
Zou, Heshan
Wang, Zhao
Wang, Yini
author_sort Yao, Shuyan
collection PubMed
description BACKGROUND: Epstein-Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is a common subtype of HLH with heterogeneous clinical presentations from self-limited to death, of which adults are worse than children. OBJECTIVE: To establish predictors of mortality risk in adult EBV-HLH patients for timely and appropriate treatment. METHODS: Patients with confirmed EBV-HLH admitted to Beijing Friendship Hospital from January 2015 to December 2019 were enrolled and statistical analysis of their laboratory test results was performed. RESULTS: Among 246 adult patients with EBV-HLH, the deceased were older (p < 0.05), with fewer blood cells (p < 0.05), poorer renal function (p < 0.01), higher levels of procalcitonin (PCT) (p < 0.01), as well as soluble interleukin-2 receptor (sCD25) (p < 0.01). The overall median survival time of patients was 135 days, 87 days for patients without transplantation and 294 days with transplantation (p < 0.001). A combined index of sCD25, PCT, and estimated glomerular filtration rate (eGFR) was obtained to predict prognosis, named the Improved HLH index (IH index), and patients were divided into three groups meeting IH- (i.e. sCD25 ≤ 18,000 pg/mL, PCT ≤ 1.8 ng/mL, eGFR ≥ 90 mL/min/1.73m(2)), IH1+ (i.e. only sCD25 > 18,000 pg/mL or only eGFR < 90 mL/min/1.73m(2)), and IH2+ (i.e. the rest), respectively. In patients with the HScore ≥ 169 or meeting HLH-04, those meeting IH2+ had significantly worse prognoses than those who met IH1+ or IH- (p < 0.001). In the group meeting IH + or IH2+, patients who received allo-HSCT had better prognoses than those who did not (p < 0.05), but there was still a significant difference in prognosis among the three groups in transplanted patients (p < 0.001). CONCLUSION: The IH index can early identify adult patients with a poor prognosis of EBV-HLH, initiating timely and appropriate treatment. KEY MESSAGES: A combined index of sCD25, PCT, and eGFR was obtained to predict prognosis, named the Improved Hemophagocytic Lymphohistiocytosis index (IH index). IH index can early identify adult patients with a poor prognosis of EBV-HLH, initiating timely and appropriate treatment.
format Online
Article
Text
id pubmed-9766494
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-97664942022-12-21 Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients Yao, Shuyan He, Lingbo Zhang, Ruoxi Liu, Menghan Hua, Zhengjie Zou, Heshan Wang, Zhao Wang, Yini Ann Med Hematology BACKGROUND: Epstein-Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is a common subtype of HLH with heterogeneous clinical presentations from self-limited to death, of which adults are worse than children. OBJECTIVE: To establish predictors of mortality risk in adult EBV-HLH patients for timely and appropriate treatment. METHODS: Patients with confirmed EBV-HLH admitted to Beijing Friendship Hospital from January 2015 to December 2019 were enrolled and statistical analysis of their laboratory test results was performed. RESULTS: Among 246 adult patients with EBV-HLH, the deceased were older (p < 0.05), with fewer blood cells (p < 0.05), poorer renal function (p < 0.01), higher levels of procalcitonin (PCT) (p < 0.01), as well as soluble interleukin-2 receptor (sCD25) (p < 0.01). The overall median survival time of patients was 135 days, 87 days for patients without transplantation and 294 days with transplantation (p < 0.001). A combined index of sCD25, PCT, and estimated glomerular filtration rate (eGFR) was obtained to predict prognosis, named the Improved HLH index (IH index), and patients were divided into three groups meeting IH- (i.e. sCD25 ≤ 18,000 pg/mL, PCT ≤ 1.8 ng/mL, eGFR ≥ 90 mL/min/1.73m(2)), IH1+ (i.e. only sCD25 > 18,000 pg/mL or only eGFR < 90 mL/min/1.73m(2)), and IH2+ (i.e. the rest), respectively. In patients with the HScore ≥ 169 or meeting HLH-04, those meeting IH2+ had significantly worse prognoses than those who met IH1+ or IH- (p < 0.001). In the group meeting IH + or IH2+, patients who received allo-HSCT had better prognoses than those who did not (p < 0.05), but there was still a significant difference in prognosis among the three groups in transplanted patients (p < 0.001). CONCLUSION: The IH index can early identify adult patients with a poor prognosis of EBV-HLH, initiating timely and appropriate treatment. KEY MESSAGES: A combined index of sCD25, PCT, and eGFR was obtained to predict prognosis, named the Improved Hemophagocytic Lymphohistiocytosis index (IH index). IH index can early identify adult patients with a poor prognosis of EBV-HLH, initiating timely and appropriate treatment. Taylor & Francis 2022-12-19 /pmc/articles/PMC9766494/ /pubmed/36533966 http://dx.doi.org/10.1080/07853890.2022.2149850 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Hematology
Yao, Shuyan
He, Lingbo
Zhang, Ruoxi
Liu, Menghan
Hua, Zhengjie
Zou, Heshan
Wang, Zhao
Wang, Yini
Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients
title Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients
title_full Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients
title_fullStr Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients
title_full_unstemmed Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients
title_short Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients
title_sort improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult epstein-barr virus-associated hlh patients
topic Hematology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9766494/
https://www.ncbi.nlm.nih.gov/pubmed/36533966
http://dx.doi.org/10.1080/07853890.2022.2149850
work_keys_str_mv AT yaoshuyan improvedhemophagocyticlymphohistiocytosisindexpredictsprognosisofadultepsteinbarrvirusassociatedhlhpatients
AT helingbo improvedhemophagocyticlymphohistiocytosisindexpredictsprognosisofadultepsteinbarrvirusassociatedhlhpatients
AT zhangruoxi improvedhemophagocyticlymphohistiocytosisindexpredictsprognosisofadultepsteinbarrvirusassociatedhlhpatients
AT liumenghan improvedhemophagocyticlymphohistiocytosisindexpredictsprognosisofadultepsteinbarrvirusassociatedhlhpatients
AT huazhengjie improvedhemophagocyticlymphohistiocytosisindexpredictsprognosisofadultepsteinbarrvirusassociatedhlhpatients
AT zouheshan improvedhemophagocyticlymphohistiocytosisindexpredictsprognosisofadultepsteinbarrvirusassociatedhlhpatients
AT wangzhao improvedhemophagocyticlymphohistiocytosisindexpredictsprognosisofadultepsteinbarrvirusassociatedhlhpatients
AT wangyini improvedhemophagocyticlymphohistiocytosisindexpredictsprognosisofadultepsteinbarrvirusassociatedhlhpatients